Plus Therapeutics

Compare

1,455 Followers

PSTV Stock Chart & Stats

$0.58

-$0.05(-4.03%)

At close: Jan 08 4:00 PM EST

$0.58

-$0.05(-4.03%)

Day’s Range― - ―

52-Week Range$0.16 - $2.31

Previous CloseN/A

Volume69.06K

Average Volume (3M)33.37M

Market Cap

$53.75M

Enterprise ValueN/A

Total Cash (Recent Filing)$9.87M

Total Debt (Recent Filing)$40.00K

Price to Earnings (P/E)―

Beta1.99

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding99,264,530

10 Day Avg. Volume10,320,100

30 Day Avg. Volume33,374,411

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$8.00

Price Target Upside1279.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Partnership And CoverageA major National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide has been announced, enhancing its market potential.

R&D FundingPlus Therapeutics received significant grants totaling $21 million for studying leptomeningeal metastases and pediatric brain cancer.

Strategic ExpansionThe company received Clinical Laboratory Improvement Amendments certification, which is a major step in expanding the availability of CNSide nationwide.

Bears Say

Business RisksRisks identified for the company include clinical, commercial, partnership, financial, and intellectual property challenges.

Plus Therapeutics News

Plus Therapeutics provides update on CNSide Diagnostic platform launch

Plus Therapeutics (PSTV) announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary,...

9d ago

PSTV

Plus Therapeutics’ ARISE Study: A New Hope for Fertility Treatment

Plus Therapeutics (($PSTV)) announced an update on their ongoing clinical study. Plus Therapeutics is advancing a pivotal study...

3d ago

PSTV

Plus Therapeutics Signs Lease Agreement in Houston

An update from Plus Therapeutics ( ($PSTV) ) is now available. On October 16, 2025, Plus Therapeutics, Inc....

9d ago

PSTV

PSTV Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Plus Therapeutics (PSTV) is scheduled to report 3rd quarter earnings on 10/16/2025. Regarding Q3 estimates, Wall Street analysts...

17d ago

PSTV

Buy Rating for Plus Therapeutics Driven by Strategic Advancements and Market Expansion for CNSide Test

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Plus Therapeutics. The associated price target...

1M ago

PSTV

Buy Rating for Plus Therapeutics Driven by CNSide Coverage and Promising Pipeline Developments

In a report released today, Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Plus Therapeutics,...

1M ago

PSTV

Plus Therapeutics announces national coverage agreement with UnitedHealthcare

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), announced that it has signed a national agreement with...

1M ago

UNH

PSTV

Plus Therapeutics announces $1.9M advance payment from CPRIT

Plus Therapeutics (PSTV) announces that the Company received notice of an additional advance payment from the Cancer Prevention...

1M ago

PSTV

Plus Therapeutics announces accreditation, certification for CNSide Diagnostics

CNSide Diagnostics received a certificate of accreditation from CMS for its lab located in Houston, Texas. Following the...

1M ago

PSTV

Plus Therapeutics upgraded to Buy from Hold at D. Boral Capital

D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics (PSTV) to Buy from Hold with a $5 price...

2M ago

PSTV

Plus Therapeutics regains compliance with applicable Nasdaq listing criteria

Plus Therapeutics (PSTV) announced that it received a letter from Nasdaq on August 22, 2025, confirming its compliance...

2M ago

PSTV

Plus Therapeutics Secures Nasdaq Compliance Extension

Plus Therapeutics ( ($PSTV) ) has shared an update. On August 22, 2025, Plus Therapeutics, Inc. received confirmation...

2M ago

PSTV

Plus Therapeutics price target lowered to $3 from $4 at Maxim

Maxim lowered the firm’s price target on Plus Therapeutics (PSTV) to $3 from $4 and keeps a Buy...

2M ago

PSTV

Plus Therapeutics presents results from ReSPECT-LM Phase 1 trial

Plus Therapeutics (PSTV) announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the...

2M ago

PSTV

PSTV FAQ

What was Plus Therapeutics’s price range in the past 12 months?

Plus Therapeutics lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.

What is Plus Therapeutics’s market cap?

Plus Therapeutics’s market cap is $53.75M.

When is Plus Therapeutics’s upcoming earnings report date?

Plus Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 112 days.

How were Plus Therapeutics’s earnings last quarter?

Currently, no data Available

Is Plus Therapeutics overvalued?

According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Plus Therapeutics pay dividends?

Plus Therapeutics does not currently pay dividends.

What is Plus Therapeutics’s EPS estimate?

Plus Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Plus Therapeutics have?

Plus Therapeutics has 99,264,530 shares outstanding.

What happened to Plus Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Plus Therapeutics?

Currently, no hedge funds are holding shares in PSTV

Plus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-7.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Plus Therapeutics

Plus Therapeutics, Inc. (PSTV) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company is primarily engaged in the development of its lead product candidate, Rhenium-186 NanoLiposome, which is designed for the targeted treatment of brain cancer and other tumors. Plus Therapeutics operates in the biopharmaceutical sector, aiming to provide advanced treatment options that enhance patient outcomes through novel delivery mechanisms and formulations.

Plus Therapeutics (PSTV) Earnings & Revenues

Historic Earnings Reports

PSTV Stock 12 Month Forecast

Average Price Target

$8.00

▲(1279.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","-1":"-$1","4.75":"$4.75","10.5":"$10.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.75,10.5,16.25,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,2.0123076923076924,3.594615384615385,5.176923076923077,6.759230769230769,8.341538461538462,9.923846153846155,11.506153846153847,13.088461538461539,14.670769230769231,16.253076923076925,17.835384615384616,19.41769230769231,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,1.0123076923076924,1.5946153846153845,2.176923076923077,2.7592307692307694,3.3415384615384616,3.923846153846154,4.506153846153846,5.088461538461538,5.67076923076923,6.2530769230769225,6.835384615384615,7.417692307692308,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.43,0.6276923076923077,0.8253846153846154,1.023076923076923,1.2207692307692306,1.4184615384615382,1.616153846153846,1.8138461538461537,2.0115384615384615,2.209230769230769,2.4069230769230767,2.6046153846153843,2.8023076923076924,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.72,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.43,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >